Patient Alerting Logistics Launches Medical Device Tracking and Critical Healthcare Messaging Service

Patient Alerting Logistics today announced the commercial launch of its revolutionary digital communications platform connecting the complete healthcare ecosystem for crucial near real-time messaging for medical devices and other critical healthcare issues.

Patient Alerting Logistics reports this first-ever computerized, managed service offering connects device manufacturers, distributors, hospitals, physicians, regulators, researchers, and patients to help promote safety and regulatory compliance. Simultaneous with the launch, PAL also named two industry veterans to lead its sales success.

PAL – Facilitating Communications Across the Complete Healthcare Ecosystem

A sophisticated, computerized communications hub, the PAL platform aggregates and shares relevant device information from traditionally fragmented sources and works continuously to ensure communication links are current, fast, and secure.  The platform can track an implanted device throughout its entire useful life, from initial manufacture to explant.  It seamlessly integrates with an EMR to automatically associate a patient with a specific device. The PAL platform replaces existing data silos as well as many traditionally disjointed manual processes, including communication through the postal system, with an advanced, automated system to ensure: Message sent. Message delivered. Every time.

Benefitting device manufacturers in particular, PAL seamlessly captures FDA-mandated device tracking information from healthcare providers and other final device distributors.  Using PAL, a manufacturer can issue a device recall in minutes, if needed.  Notifications are delivered immediately to potentially impacted patients, hospitals, and other relevant healthcare constituents, potentially sparing patient harm, lives, and legal actions. Additionally, the platform tracks information the FDA may require from vendors for post-market device surveillance. It also streamlines healthcare provider compliance with required patient information updates, supporting faster and more accurate device information flow throughout the healthcare system.

“PAL answers a significant, long-overdue need,” comments Paul Dandrow, PAL Chairman and CEO.  “Device tracking, in particular, and communications across the global healthcare ecosystem are mired in antiquated processes, diminishing quality of care and negatively impacting every stakeholder.  Even prior to our service’s launch, we have already received significant interest in our innovative service offering from across the industry.  The addition of these two strong industry sales leaders will allow us to convert that interest into continued success and rapid growth.”

Timothy Chunn, Vice President of Sales for Medical Device Manufacturers

Timothy Chunn, a 25-year healthcare technology veteran with broad IT experience, joins PAL as Vice President of Sales for Medical Device Manufacturers.  He will be responsible for formulating sales strategies, promoting PAL’s service offerings, and building long-term relationships in the device manufacturing marketplace. Most recently, as a business development director for NetApp IT, Mr. Chunn expanded the company’s global business with direct sales teams and developed new channel partners, software introductions, and analytics alliances. During his career he has also held executive leadership positions at BridgeHead Software, Dell Healthcare & Life Sciences, Symantec, and Bycast.

Perrish Dailey, Vice President of Sales for Healthcare Providers

Perrish Dailey joins PAL as Vice President of Sales for Healthcare Providers, bringing 25 years of successful sales leadership experience to the company.  Mr. Dailey will be responsible for developing and implementing field sales strategies and tactics and managing ongoing customer relationships. He excels at helping to develop and deliver new technology solutions and supporting them through outstanding sales leadership and customer service that drive exponential revenue growth. Most recently, Mr. Dailey was President and Chief Operations Officer at Rivera Group where he was responsible for complete corporate operations for the innovative cybersecurity firm.  During his career, he also held successive leadership positions focused on healthcare at Dell, culminating in Global Director for Dell Services.

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.